Merus Profit Margin 2016-2021 | MRUS
Current and historical gross margin, operating margin and net profit margin for Merus (MRUS) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Merus net profit margin as of September 30, 2021 is -185.1%.
|Merus Annual Profit Margins
|Merus Quarterly Profit Margins
||Medical - Biomedical and Genetics
Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.